---
title: "Eritrea validated by WHO for elimination of trachoma as a public health problem"
id: "who-0-4-eritrea-eliminates-trachoma-a-major-public-health-milestone"
canonical_url: "https://medichelpline.com/clinical-feed/who-0-4-eritrea-eliminates-trachoma-a-major-public-health-milestone"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "World Health Organization"
source_url: "https://www.who.int/news/item/16-11-2026-eritrea-eliminates-trachoma-a-major-public-health-milestone"
published_at: "2026-11-16T12:00:00.000Z"
evidence_level: "News release"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Eritrea validated by WHO for elimination of trachoma as a public health problem
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/who-0-4-eritrea-eliminates-trachoma-a-major-public-health-milestone
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** World Health Organization
- **Source URL:** [Original Journal Publication](https://www.who.int/news/item/16-11-2026-eritrea-eliminates-trachoma-a-major-public-health-milestone)
- **Published At:** 2026-11-16T12:00:00.000Z
- **Evidence Rating:** News release
## Executive GIST (TL;DR)
- WHO validated that Eritrea has eliminated **trachoma** as a public health problem, making it the 11th African country and the 34th globally to reach this milestone. - Validation followed national surveys done between 2006 and 2020 and a dossier review by a WHO-appointed group that confirmed epidemiological thresholds were met. - Eritrea implemented the **SAFE strategy** (Surgery, Antibiotics, Facial cleanliness, Environmental improvement) progressively in endemic areas. - The national programme surveyed all 58 sub-zobas, scaled up interventions where needed, and used digital tools for data collection and mapping. - Antibiotics distributed were mainly oral **azithromycin**, donated through the International Trachoma Initiative; the source reported this but did not specify dosing regimens. - The programme used a community-led sanitation approach that achieved gains with limited external funding, according to WHO statements. - Systems are now in place in Eritrea to identify and manage new trichiasis cases; ongoing surveillance will continue after validation. - WHO Director-General Dr Tedros Adhanom Ghebreyesus and WHO Representative Dr Mary Stephen publicly congratulated the Government and communities for leadership and partnerships. - Global context reported by WHO: the population requiring trachoma interventions fell from an estimated 1.5 billion in 2002 to below 100 million by November 2025; however, as of March 2026, 92 million people still lived in trachoma-endemic areas. - The source noted that trachoma remained a public health problem in parts of 29 countries, and that in 2025 nearly 98,829 people received trichiasis surgery while 47.4 million received antibiotics. - Eritrea was reported as the 66th country globally and 23rd in the WHO African Region to eliminate at least one neglected tropical disease; the source did not provide detailed programmatic cost data or specific surveillance metrics post-validation.
## Clinical Analysis & Structured Key Points
[Skip to main content](https://www.who.int/news/item/16-11-2026-eritrea-eliminates-trachoma-a-major-public-health-milestone#content) * [ ](https://www.who.int/) [Global](https://www.who.int/) * [Regions](https://www.who.int/news/item/16-11-2026-eritrea-eliminates-trachoma-a-major-public-health-milestone) WHO Regional websites * [ Africa ](https://www.afro.who.int/) * [ Americas ](https://www.paho.org/en) * [ South-East Asia ](https://www.who.int/southeastasia) * [ Europe ](https://www.who.int/europe/) * [ Eastern Mediterranean ](http://www.emro.who.int/index.html) * [ Western Pacific ](https://www.who.int/westernpacific/) When autocomplete results are available use up and down arrows to review and enter to select. Select language Select language English العربية 中文 Français Русский Español Português [ ](https://www.who.int/ "Home") * [Home](https://www.who.int/) * [Health Topics](https://www.who.int/mega-menu/health-topics) * [Countries](https://www.who.int/mega-menu/countries) * [Newsroom](https://www.who.int/news-room) * [Emergencies](https://www.who.int/mega-menu/emergencies) * [Data](https://www.who.int/mega-menu/data) * [About WHO](https://www.who.int/mega-menu/about-us) * [Home](https://www.who.int/) * [Health Topics](https://www.who.int/mega-menu/health-topics) * [Countries](https://www.who.int/mega-menu/countries) * [Newsroom](https://www.who.int/news-room) * [Emergencies](https://www.who.int/mega-menu/emergencies) * [Data](https://www.who.int/mega-menu/data) * [About WHO](https://www.who.int/mega-menu/about-us) * [All topics](https://www.who.int/health-topics/) * [A](https://www.who.int/health-topics/#A) * [B](https://www.who.int/health-topics/#B) * [C](https://www.who.int/health-topics/#C) * [D](https://www.who.int/health-topics/#D) * [E](https://www.who.int/health-topics/#E) * [F](https://www.who.int/health-topics/#F) * [G](https://www.who.int/health-topics/#G) * [H](https://www.who.int/health-topics/#H) * [I](https://www.who.int/health-topics/#I) * [J](https://www.who.int/health-topics/#J) * [K](https://www.who.int/health-topics/#K) * [L](https://www.who.int/health-topics/#L) * [M](https://www.who.int/health-topics/#M) * [N](https://www.who.int/health-topics/#N) * [O](https://www.who.int/health-topics/#O) * [P](https://www.who.int/health-topics/#P) * [Q](https://www.who.int/health-topics/#Q) * [R](https://www.who.int/health-topics/#R) * [S](https://www.who.int/health-topics/#S) * [T](https://www.who.int/health-topics/#T) * [U](https://www.who.int/health-topics/#U) * [V](https://www.who.int/health-topics/#V) * [W](https://www.who.int/health-topics/#W) * [X](https://www.who.int/health-topics/#X) * [Y](https://www.who.int/health-topics/#Y) * [Z](https://www.who.int/health-topics/#Z) * [Resources](https://www.who.int/mega-menu/health-topics/resources) * [Fact sheets](https://www.who.int/mega-menu/health-topics/resources/fact-sheets) * [Facts in pictures](https://www.who.int/mega-menu/health-topics/resources/facts-in-pictures) * [Multimedia](https://www.who.int/mega-menu/health-topics/resources/multimedia) * [Podcasts](https://www.who.int/mega-menu/health-topics/resources/podcasts) * [Publications](https://www.who.int/mega-menu/health-topics/resources/publications) * [Questions and answers](https://www.who.int/mega-menu/health-topics/resources/questions-and-answers) * [Tools and toolkits](https://www.who.int/mega-menu/health-topics/resources/tools-and-toolkits) * [Popular](https://www.who.int/mega-menu/health-topics/popular) * [Dengue](https://www.who.int/mega-menu/health-topics/popular/dengue) * [Endometriosis](https://www.who.int/mega-menu/health-topics/popular/endometriosis) * [Excessive heat](https://www.who.int/mega-menu/health-topics/popular/excessive-heat) * [Herpes](https://www.who.int/mega-menu/health-topics/popular/herpes) * [Mental disorders](https://www.who.int/mega-menu/health-topics/popular/mental-disorders) * [Mpox](https://www.who.int/mega-menu/health-topics/popular/mpox) * [All countries](https://www.who.int/countries) * [A](https://www.who.int/countries/#A) * [B](https://www.who.int/countries/#B) * [C](https://www.who.int/countries/#C) * [D](https://www.who.int/countries/#D) * [E](https://www.who.int/countries/#E) * [F](https://www.who.int/countries/#F) * [G](https://www.who.int/countries/#G) * [H](https://www.who.int/countries/#H) * [I](https://www.who.int/countries/#I) * [J](https://www.who.int/countries/#J) * [K](https://www.who.int/countries/#K) * [L](https://www.who.int/countries/#L) * [M](https://www.who.int/countries/#M) * [N](https://www.who.int/countries/#N) * [O](https://www.who.int/countries/#O) * [P](https://www.who.int/countries/#P) * [Q](https://www.who.int/countries/#Q) * [R](https://www.who.int/countries/#R) * [S](https://www.who.int/countries/#S) * [T](https://www.who.int/countries/#T) * [U](https://www.who.int/countries/#U) * [V](https://www.who.int/countries/#V) * [W](https://www.who.int/countries/#W) * [X](https://www.who.int/countries/#X) * [Y](https://www.who.int/countries/#Y) * [Z](https://www.who.int/countries/#Z) * [Regions](https://www.who.int/mega-menu/countries/regions) * [Africa](https://www.who.int/mega-menu/countries/regions/africa) * [Americas](https://www.who.int/mega-menu/countries/regions/americas) * [Europe](https://www.who.int/mega-menu/countries/regions/europe) * [Eastern Mediterranean](https://www.who.int/mega-menu/countries/regions/eastern-mediterranean) * [South-East Asia ](https://www.who.int/mega-menu/countries/regions/south-east-asia) * [Western Pacific](https://www.who.int/mega-menu/countries/regions/western-pacific) * [WHO in countries](https://www.who.int/mega-menu/countries/who-in-countries) * [Data by country](https://www.who.int/mega-menu/countries/who-in-countries/data-by-country) * [Country presence ](https://www.who.int/mega-menu/countries/who-in-countries/country-presence) * [Country cooperation strategies ](https://www.who.int/mega-menu/countries/who-in-countries/country-cooperation-strategies) * [Country office profiles](https://www.who.int/mega-menu/countries/who-in-countries/country-office-profiles) * [Strengthening country offices ](https://www.who.int/mega-menu/countries/who-in-countries/country-strengthening) * [Newsroom](https://www.who.int/mega-menu/news/all-news) * [News releases](https://www.who.int/mega-menu/news/all-news/releases) * [Statements](https://www.who.int/mega-menu/news/all-news/statements) * [Campaigns](https://www.who.int/mega-menu/news/all-news/campaigns) * [Events](https://www.who.int/mega-menu/news/all-news/events) * [Feature stories](https://www.who.int/mega-menu/news/all-news/feature-stories) * [Speeches](https://www.who.int/mega-menu/news/all-news/speecheshub) * [Commentaries](https://www.who.int/mega-menu/news/all-news/commentaries) * [Photo library](https://www.who.int/mega-menu/news/all-news/photo-library) * [Headlines](https://www.who.int/news-room/headlines) * [In focus](https://www.who.int/mega-menu/emergencies/emergencies) * [Cholera ](https://www.who.int/mega-menu/emergencies/emergencies/cholera) * [Ebola disease](https://www.who.int/mega-menu/emergencies/emergencies/ebola-disease) * [Israel and the occupied Palestinian territory](https://www.who.int/mega-menu/emergencies/emergencies/israel-and-occupied-palestinian-territory) * [Middle East](https://www.who.int/mega-menu/emergencies/emergencies/middle-east) * [Sudan](https://www.who.int/mega-menu/emergencies/emergencies/sudan) * [Ukraine](https://www.who.int/mega-menu/emergencies/emergencies/ukraine-emergency) * [Latest](https://www.who.int/mega-menu/emergencies/news) * [Disease Outbreak News](https://www.who.int/mega-menu/emergencies/news/disease-outbreak-news) * [Situation reports](https://www.who.int/mega-menu/emergencies/news/situation-reports) * [Rapid risk assessments](https://www.who.int/mega-menu/emergencies/news/rapid-risk-assessment) * [Weekly Epidemiological Record](https://www.who.int/mega-menu/emergencies/news/weekly-epidemiological-record) * [WHO in emergencies](https://www.who.int/mega-menu/emergencies/who-in-emergencies) * [Surveillance](https://www.who.int/mega-menu/emergencies/who-in-emergencies/surveillance) * [Alert and response](https://www.who.int/mega-menu/emergencies/who-in-emergencies/alert-and-response) * [Operations](https://www.who.int/mega-menu/emergencies/who-in-emergencies/operations) * [Research](https://www.who.int/mega-menu/emergencies/who-in-emergencies/research-development) * [Funding](https://www.who.int/mega-menu/emergencies/who-in-emergencies/funding) * [Partners](https://www.who.int/mega-menu/emergencies/who-in-emergencies/partners) * [Health emergency appeals](https://www.who.int/mega-menu/emergencies/who-in-emergencies/health-emergency-appeal) * [International Health Regulations](https://www.who.int/mega-menu/emergencies/who-in-emergencies/international-health-regulations) * [Independent Oversight and Advisory Committee](https://www.who.int/mega-menu/emergencies/who-in-emergencies/independent-oversight-and-advisory-committee) * [Data at WHO](https://www.who.int/mega-menu/data/data-who) * [Data hub](https://www.who.int/mega-menu/data/data-who/data-hub) * [Global Health Estimates](https://www.who.int/mega-menu/data/data-who/global-health-estimates) * [Health inequality](https://www.who.int/mega-menu/data/data-who/health-inequality) * [Global Health Observatory](https://www.who.int/mega-menu/data/data-who/global-health-obsevatory) * [Dashboards](https://www.who.int/mega-menu/data/dashboards) * [Triple Billion Progress](https://www.who.int/mega-menu/data/dashboards/triple-billion-progress) * [Health Inequality Monitor](https://www.who.int/mega-menu/data/dashboards/health-inequality-monitor) * [Delivery for impact](https://www.who.int/mega-menu/data/dashboards/delivery-for-impact) * [COVID-19 dashboard](https://www.who.int/mega-menu/data/dashboards/covid-19-dashboard) * [Data collection](https://www.who.int/mega-menu/data/data-collection) * [Classifications](https://www.who.int/mega-menu/data/data-collection/classifications) * [SCORE](https://www.who.int/mega-menu/data/data-collection/score) * [Surveys](https://www.who.int/mega-menu/data/data-collection/surveys) * [Civil registration and vital statistics](https://www.who.int/mega-menu/data/data-collection/civil-registration-and-vital-statistics) * [Routine health information systems](https://www.who.int/mega-menu/data/data-collection/routine-health-information-systems) * [Harmonized health facility assessment](https://www.who.int/mega-menu/data/data-collection/harmonized-health-facility-assessment) * [GIS centre for health](https://www.who.int/mega-menu/data/data-collection/gis-centre-for-health) * [Reports](https://www.who.int/mega-menu/data/reports) * [World Health Statistics](https://www.who.int/mega-menu/data/reports/world-health-statistics) * [UHC global monitoring report](https://www.who.int/mega-menu/data/reports/uhc-global-monitoring-report) * [About WHO](https://www.who.int/mega-menu/about-us/about) * [Partnerships](https://www.who.int/mega-menu/about-us/about/partnerships-and-collaboration) * [Committees and advisory groups](https://www.who.int/mega-menu/about-us/about/expert-groups) * [Collaborating centres](https://www.who.int/mega-menu/about-us/about/collaborating-centres) * [Technical teams](https://www.who.int/mega-menu/about-us/about/teams) * [Organizational structure](https://www.who.int/mega-menu/about-us/about/structure) * [Who we are](https://www.who.int/mega-menu/about-us/about/who-we-are) * [Our work](https://www.who.int/mega-menu/about-us/our-work) * [Activities](https://www.who.int/mega-menu/about-us/our-work/activities) * [Initiatives](https://www.who.int/mega-menu/about-us/our-work/initiatives) * [General Programme of Work](https://www.who.int/mega-menu/about-us/our-work/global-programme-of-work) * [WHO Academy](https://www.who.int/mega-menu/about-us/our-work/who-academy) * [Funding](https://www.who.int/mega-menu/about-us/who-funding) * [Investment in WHO](https://www.who.int/mega-menu/about-us/who-funding/investment-case) * [WHO Foundation](https://www.who.int/mega-menu/about-us/who-funding/who-foundation) * [Accountability](https://www.who.int/mega-menu/about-us/accountability) * [External audit](https://www.who.int/mega-menu/about-us/accountability/audit) * [Financial statements](https://www.who.int/mega-menu/about-us/accountability/financial-statements) * [Internal audit and investigations ](https://www.who.int/mega-menu/about-us/accountability/internal-audit-and-investigations) * [Programme Budget](https://www.who.int/mega-menu/about-us/accountability/budget) * [Results reports](https://www.who.int/mega-menu/about-us/accountability/results-report) * [Governance](https://www.who.int/mega-menu/about-us/governance) * [Governing bodies](https://www.who.int/mega-menu/about-us/governance/governing-bodies-website) * [World Health Assembly](https://www.who.int/mega-menu/about-us/governance/wha) * [Executive Board](https://www.who.int/mega-menu/about-us/governance/eb) * [Member States Portal](https://www.who.int/mega-menu/about-us/governance/member-states-portal) * [Home](https://www.who.int/)/ * [News](https://www.who.int/news)/ * Eritrea eliminates trachoma: a major public health milestone Ministry of Health, Eritrea A woman being examined for trachomatous trichiasis. © Credits # Eritrea eliminates trachoma: a major public health milestone 16 November 2026 News release Asmara/Brazzaville/Geneva Reading time: 3 min (882 words) The World Health Organization (WHO) has validated Eritrea's elimination of trachoma as a public health problem, making it the 11th country in WHO’s African Region and the 34th globally to reach this major milestone. “I congratulate the Government and people of Eritrea on this historic achievement,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “After two decades of determined effort, Eritrea has consigned trachoma as a public health problem to history. This is a victory for the communities most affected by this devastating disease, and a powerful example of what sustained national commitment can achieve.” In Eritrea, many people live in remote rural areas where access to health care and clean water and sanitation can be limited, creating conditions that facilitate the transmission of trachoma. Following baseline surveys conducted in different parts of the country between 2006 and 2020, Eritrea progressively implemented [WHO’s recommended SAFE strategy](https://www.who.int/activities/improving-treatment-for-snakebite-patients) in communities where interventions were needed. The strategy comprises surgery for trachomatous trichiasis, antibiotics to clear infection, facial cleanliness to reduce transmission, and environmental improvement, particularly improved access to water and sanitation. “I congratulate Eritrea on this historic public health milestone. It shows what is possible through sustained political commitment, community leadership and strong partnerships,” said Dr Mohamed Janabi. “Eritrea’s achievement brings us closer to a world free from the suffering caused by neglected tropical diseases and sends a strong message of hope to other African countries working towards trachoma elimination. With determination and collective action, we can protect the health and well-being of communities and leave no one behind.” Eritrea’s programme adopted a community-led sanitation approach that helped achieve significant public health gains with limited external funding. Health workers used digital tools for data collection and mapping to identify affected communities and target resources, including in hard-to-reach areas. The country surveyed all 58 sub-zobas (second-level administrative areas) and scaled up interventions wherever trachoma was endemic. The antibiotics distributed were predominantly oral azithromycin, donated by Pfizer Inc. through the International Trachoma Initiative. Eritrea has also established systems to identify and manage new trichiasis cases and will continue surveillance following validation. "This success belongs first and foremost to the people of Eritrea. The elimination of trachoma as a public health problem is the result of strong national leadership and ownership, and collaboration between communities, the Ministry of Health, the Fred Hollow's Foundation, development partners and health workers across the country,” said Dr Mary Stephen, WHO Representative to Eritrea. “WHO is proud to have supported Eritrea throughout this journey and will continue to work closely with the Government and partners to sustain these gains.” ## Notes to editors ### About trachoma [Trachoma](https://www.who.int/news-room/fact-sheets/detail/trachoma) is the world’s leading infectious cause of blindness. It is caused by the bacterium _Chlamydia trachomatis_ and spreads through contact with eye and nasal discharge from infected individuals. Repeated infections can lead to scarring of the inner eyelid, causing the eyelashes to turn inward (trichiasis), which can ultimately result in blindness. The disease is closely associated with poverty and inequities in access to basic services, including water, sanitation and hygiene and health care, and it remains endemic in some of the world's most vulnerable communities. WHO validates elimination only after receiving a recommendation from an independent, WHO-appointed dossier review group on the evidence submitted by a country, confirming that the agreed epidemiological thresholds have been met and that systems are in place to detect and manage future cases. Validation provides independent confirmation that a country has achieved the criteria for eliminating trachoma as a public health problem. Based on the latest WHO data, the global population requiring interventions against trachoma fell from an estimated 1.5 billion in 2002 to below 100 million by November 2025, a reduction of about 94%. However, as of March 2026, 92 million people still lived in trachoma-endemic areas and were at risk of trachoma blindness, and trachoma remained a public health problem in at least part of 29 countries. In 2025, 98 829 people received surgery for the advanced stage of the disease and 47.4 million received antibiotics. Trachoma is one of the 21 diseases and disease groups currently covered by the [road map for neglected tropical diseases 2021–2030](https://www.who.int/publications/i/item/9789240010352). NTDs affect more than 1 billion people, particularly people living in poverty and in remote or fragile settings with limited access to essential health services. The road map for neglected tropical diseases 2021–2030, endorsed by the World Health Assembly in 2020, sets global targets for the prevention, control, elimination and eradication of these diseases. Eritrea became the 66th country globally and the 23rd in the WHO African Region to have eliminated at least one neglected tropical disease. ### About WHO Dedicated to the well-being of all people and guided by science, WHO leads and champions global efforts to give everyone, everywhere, an equal chance at a safe and healthy life. We are the United Nations’ agency for health that connects nations, partners and people in more than 150 locations – leading the world’s response to health emergencies, preventing disease, addressing the root causes of health issues and expanding access to medicines and health care. Our mission
## Related Clinical Research

- [Macrolide-Resistant Bordetella pertussis Detected in Peru During 2025 Outbreak](https://medichelpline.com/clinical-feed/cdc-emerging-infectious-diseases-journal-2-emergence-of-macrolide-resistant-bordetella-pertussis-peru-2025.md)
- [Tuberculosis screening and tuberculin skin test performance in adults with inborn errors of immuni](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-tuberculosis-screening-in-adult-patients-with-inborn-errors-of-immunity-a.md)
- [Intrapartum oral azithromycin vs placebo for maternal infection in South East Asia](https://medichelpline.com/clinical-feed/pubmed-43050477.md) (DOI: 10.1371/journal.pone.0346359)
- [Pharyngeal Gonorrhea vs Urogenital Strains in Ugandan Men: AMR and Genomic Differences](https://medichelpline.com/clinical-feed/pubmed-42415364.md) (DOI: 10.1093/infdis/jiag353)
- [Azithromycin MDA and antimicrobial resistance in Mali: LAKANA trial sub-study results](https://medichelpline.com/clinical-feed/plos-medicine-0-analysis-of-antimicrobial-resistance-in-the-lakana-trial-of-azithromycin.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.